Yervoy Off to Strong Start, Says BMS' Tony Hooper
This article was originally published in The Pink Sheet Daily
The launch of Bristol's metastatic melanoma therapy is off to a strong start, but uncertainties linger, including whether the drug will compete with Roche's BRAF inhibitor.
You may also be interested in...
New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.
Company details "new customer model" with an integrated reimbursement and medical support team that is being rolled out for the ipilimumab launch.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?